Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

E. Sands, Bruce; J. Sandborn, William; Van Assche, Gert; Lukáš, Milan; Xu, Jing; James, Alexandra; Abhyankar, Brihad; Lasch, Karen

doi:10.1097/mib.0000000000000979

Public

Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

Published in Inflammatory Bowel Diseases • Dec 8, 2016

Authors:

Bruce E. Sands

William J. Sandborn

Gert Van Assche

Abstract

BACKGROUND: Vedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims of this study were to characterize the efficacy and safety of vedolizumab induction and maintenance therapy in patients who were naïve to tumor necrosis f...

Subject

Vedolizumab

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!